Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tiziana Life Sciences Ltd - Common Shares
(NQ:
TLSA
)
0.6815
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tiziana Life Sciences Ltd - Common Shares
< Previous
1
2
3
4
5
6
7
8
Next >
EXCLUSIVE: Top Tesla Options Trades Recommended By Trading Expert
May 15, 2024
Trading expert Anne-Marie Baiynd shared option trade ideas for Tesla on Benzinga's YouTube, discussing potential positive catalysts and bullish strategies.
Via
Benzinga
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
May 13, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
April 25, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
April 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 23, 2024
Via
Benzinga
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
April 23, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
April 22, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
April 19, 2024
Via
Benzinga
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
April 19, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
7 Battered Blue-Chip Stocks to Bounce From Your Portfolio This Spring
April 19, 2024
Not all big companies are doing well in the stock market. For various reasons, these battered blue-chip stocks are struggling mightily.
Via
InvestorPlace
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 18, 2024
Via
Benzinga
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 18, 2024
Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 11, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
3 EV Stocks to Buy on the Dip: March 2024
March 29, 2024
The electric vehicle market slump has significantly impacted many EV stocks to buy - But the slump will not last forever.
Via
InvestorPlace
Topics
Electric Vehicles
Exposures
Electric Vehicles
3 EV Stocks to Buy for the Next Bull Run: March 2024
March 28, 2024
EV stocks have broadly underperformed the market in 2024, which has, in turn, created a number of opportunities to buy at a bargain.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 05, 2024
Via
Benzinga
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
March 05, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
7 Over-Hyped Stocks to Sell Before They Plunge
January 25, 2024
It wasn't too long ago that these stocks were considered hot commodities. But now they're just overhyped stocks to sell.
Via
InvestorPlace
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
January 08, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
January 05, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
December 19, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tesla Shares Hardly Damaged Despite Recall: Full Self-Driving Is Elon Musk's 'Holy Grail,' Analyst Says
December 13, 2023
Tesla shares fell only slightly. And auto recalls are nothing new. Recall how, in 1981, Ford issued a recall on 21 million vehicles.
Via
Benzinga
Topics
Product Recall
Exposures
Legal
Product Safety
Don't Get Caught In Equity Rally Hype: Lessons From 2023 To Remember In 2024
December 12, 2023
After a volatile 2023, equity markets appear to be rallying into 2024. Can they keep it up?
Via
Benzinga
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
December 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab
December 01, 2023
--News Direct--
Via
News Direct
Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab
November 30, 2023
This month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS)...
Via
Benzinga
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
November 30, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
SPDR ETF Report For Tuesday, November 21
November 22, 2023
Via
Talk Markets
Topics
ETFs
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.